Skip to main content
. 2023 Jan 3;80(2):380–391. doi: 10.1007/s12020-022-03281-8

Fig. 3.

Fig. 3

a Evolution of anti-TPO titres over 6 months (p = 0.070); b Evolution of anti-TPO titres over 6 months, stratified by interferon exposure in acute COVID-19. *p < 0.05 compared with baseline among interferon-treated patients; #p < 0.05 compared with baseline among interferon-naïve patients